# Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

> **NCT00910000** · PHASE1,PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 15 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00910000
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2013-01
- **Final completion:** 2015-10
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Terminated due to unacceptable toxicity
- **Last updated:** 2018-09-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910000, "Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00910000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*